In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline]

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2954-2962

  Uckun, Fatih M ^a,b   Onur, Ek ^a   Xin Ping, Liu ^b   Chen, Chun Lin ^a,b  

^a Parker Hughes Cancer Center   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CYTOPATHOGENIC EFFECT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG ELIMINATION; DRUG PROTEIN BINDING; ENZYME SPECIFICITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; JANUS KINASE 3; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RATS; RATS, INBRED LEW; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0344466789     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Demoulin, J. B., Uyttenhove, C., Van Roost, E., DeLestre, B., Donckers, D., Van Snick, J., and Renauld, J. C. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. Mol. Cell. Biol., 16: 4710-4716, 1996.
2. Jurlander, J., Lai, C. F., Tan, J., Chou, C. C., Geisler, C. H., Schriber, J., Blumenson, L. E., Narula, S. K., Baumann, H., and Caligiuri, M. A. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood, 89: 4146-4152, 1997.
3. Kaneko, S., Suzuki, N., Koizumi, H. S., Yamamoto, S., and Sakane, T. Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. Clin. Exp. Immunol., 109: 185-193, 1997.
4. Nakamura, N., Chin, H., Miyasaka, N., and Miura, O. An epidermal growth factor receptor/JAK2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells. J. Biol. Chem., 277: 19483-19488, 1996.
5. Ihle, J. N. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv. Immunol., 60: 1-35, 1995.
6. Witthuhn, B. A., Williams, M. D., Kerawalla, H., and Uckun, F. M. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery. Leuk. Lymphoma, 32: 289-297, 1999.
7. Gouilleux-Gruart, V., Gouilleux, F., Claisse, J. F., Capiod, J. C., Delobel, J., Weber-Nordt, R., Dusanter-Fourt, I., Dreyfus, F., Groner, B., and Prin, L. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood, 87: 1692-1697, 1996.
8. Weber-Nordt, R. M., Egen, C., Wehinger, J., Ludwig, W., Gouilleux-Gruart, V., Mertelsmann, R., and Finke, J. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood, 88: 809-816, 1996.
9. Sudbeck, E. A., Liu, X. P., Narla, R. K., Mahajan, S., Ghosh, S., Mao, C., and Uckun, F. M. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res., 5: 1569-1582, 1999.
10. Chen, C. L., Malaviya, R., Chen, H., Liu, X-P., and Uckun, F. M. A quantitative HPLC detection method for pharmacokinetic studies of the potent mast cell inhibitor 4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131). J. Chromatogr. B (Biomed. Sci.), 727: 205-212, 1999.
11. Chen, C. L., Malaviya, R., Navara, C., Chen, H., Bechard, B., Mitchltree, G., Eiu, X. P., and Uckun, F. M. Pharmacoikinetics and biologic activity of the novel mast cell inhibitor, 4-(3′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice. Pharm. Res., 16: 117-122, 1999.
12. Chen, C. L., Tai, H. L., Zhu, D. M., and Uckun, F. M. Pharmacokinetic features and metabolism of calphostin C, a naturally occurring perylenequinone with potent antileukemic activity. Pharm. Res., 16: 1003-1009, 1999.
13. Uckun, F. M., Narla, R., Zeren, T., Yanishevski, Y., Myers, D. E., Waurzyniak, B., Ek, O., Schneider, E., Messinger, Y., Chelstrom, L. M., Gunther, R., and Evans, W. In vivo toxicity, pharmacokinetics, and anticancer activity of genistein conjugated to human epidermal growth factor. Clin. Cancer Res., 4: 1125-1134, 1998.
14. Messinger, Y., Yanishevski, Y., Ek, O., Zeren, T., Waurzyniak, B., Gunther, R., Chelstrom, L. M., Chandan-Langlie, M., Schneider, E., Myers, D. E., Evans, W., and Uckun, F. M. In vivo toxicity and pharmacokinetic features of B43(anti-CD19)-genistein immunoconjugate in non-human primates. Clin. Cancer Res., 4: 165-170, 1998.
15. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Ahlgren, E. T., Chelstrom, L. M., Burkhardt, A., Bolen, J., and Myers, D. E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science (Washington DC), 267: 886-891, 1995.
16. Davies, B., and Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res., 10: 1093-1095, 1993.
17. Jodrell, D. I., Newell, D. R., Gibson, W., Hughes, E. R., and Calvert, A. H. The pharmacokinetics of the quinazoline antifolate ICI D1694 inmice and rats. Cancer Chemother. Pharmacol., 28: 331-338, 1991.
18. Boxenbaum, H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab. Rev., 15: 1071-1121, 1984.
19. Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., MacIntyre, F., Rance, D. J., and Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther., 283: 46-58, 1997.
20. Ritschel, W. A., Vachharajani, N. N., Johnson, R. D., and Hussain, A. S. The allometric approach for interspecies scaling of pharmacokinetic parameters. Comp. Biochem. Physiol., 103: 249-253, 1992.